154 related articles for article (PubMed ID: 35100354)
21. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I.
Oftedal BE; Wolff AS; Bratland E; Kämpe O; Perheentupa J; Myhre AG; Meager A; Purushothaman R; Ten S; Husebye ES
Clin Immunol; 2008 Oct; 129(1):163-9. PubMed ID: 18708298
[TBL] [Abstract][Full Text] [Related]
22. Comment on 'AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies'.
Landegren N; Rosen LB; Freyhult E; Eriksson D; Fall T; Smith G; Ferre EMN; Brodin P; Sharon D; Snyder M; Lionakis M; Anderson M; Kämpe O
Elife; 2019 Jun; 8():. PubMed ID: 31244471
[TBL] [Abstract][Full Text] [Related]
23. Editorial: Autoantibodies to Components of the Immune System, Including Type 1 Interferons, and the Risk of Severe COVID-19.
Parums DV
Med Sci Monit; 2021 Sep; 27():e934766. PubMed ID: 34538868
[TBL] [Abstract][Full Text] [Related]
24. Antibodies against type I IFN: The bad guys self-restrain in systemic lupus erythematosus.
Fillatreau S
Cell Rep Med; 2023 Jan; 4(1):100903. PubMed ID: 36652912
[TBL] [Abstract][Full Text] [Related]
25. Increased Presence of Antibodies against Type I Interferons and Human Endogenous Retrovirus W in Intensive Care Unit COVID-19 Patients.
Simula ER; Manca MA; Noli M; Jasemi S; Ruberto S; Uzzau S; Rubino S; Manca P; Sechi LA
Microbiol Spectr; 2022 Aug; 10(4):e0128022. PubMed ID: 35852349
[TBL] [Abstract][Full Text] [Related]
26. Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.
Solanich X; Rigo-Bonnin R; Gumucio VD; Bastard P; Rosain J; Philippot Q; Perez-Fernandez XL; Fuset-Cabanes MP; Gordillo-Benitez MÁ; Suarez-Cuartin G; Boza-Hernandez E; Riera-Mestre A; Parra-Martínez A; Colobran R; Antolí A; Navarro S; Rocamora-Blanch G; Framil M; Calatayud L; Corbella X; Casanova JL; Morandeira F; Sabater-Riera J
J Clin Immunol; 2021 Nov; 41(8):1733-1744. PubMed ID: 34570326
[TBL] [Abstract][Full Text] [Related]
27. Acquired hemophilia: we now see it with myeloproliferative neoplasms.
Kremyanskaya M; Aledort L
Am J Hematol; 2011 Mar; 86(3):329-30. PubMed ID: 21328432
[No Abstract] [Full Text] [Related]
28. Anti-Interferon Autoantibodies in Adult-Onset Immunodeficiency Syndrome and Severe COVID-19 Infection.
Chen LF; Yang CD; Cheng XB
Front Immunol; 2021; 12():788368. PubMed ID: 35003106
[TBL] [Abstract][Full Text] [Related]
29. [New biomodulator treatment, treatment with interferon alpha in hematology and treatment using interleukin 2].
Castaigne S; Degos L
Rev Prat; 1988 Jun; 38(17):1069-72. PubMed ID: 3043637
[No Abstract] [Full Text] [Related]
30. Serum type-III-procollagen and laminin concentration after interferon therapy in chronic myeloproliferative disorders.
Sréter L; Kárteszi M; Fehér J; Lutz D
Acta Med Hung; 1988; 45(3-4):323-8. PubMed ID: 3249659
[TBL] [Abstract][Full Text] [Related]
31. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
32. [Clinical features and diagnosis of Ph - negative myeloproliferative neoplasms occurring in conjunction with the antiphospholipid syndrome].
Melikyan AL; Subortseva IN; Koloshejnova EA; Gilyazitdinova EA; Shashkina KS; Gorgidze LA; Tratsevskaya ZV; Margolin OV
Ter Arkh; 2019 Jul; 91(7):93-99. PubMed ID: 32598741
[TBL] [Abstract][Full Text] [Related]
33. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.
Tichelli A; Gratwohl A; Berger C; Lori A; Würsch A; Dieterle A; Thomssen C; Nissen C; Holdener E; Speck B
Blut; 1989 Jan; 58(1):15-9. PubMed ID: 2644994
[TBL] [Abstract][Full Text] [Related]
34. Decreased natural killer (NK) activity in patients with myeloproliferative disorders.
Froom P; Aghai E; Kinarty A; Lahat N
Cancer; 1989 Sep; 64(5):1038-40. PubMed ID: 2788028
[TBL] [Abstract][Full Text] [Related]
35. Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19.
Abers MS; Rosen LB; Delmonte OM; Shaw E; Bastard P; Imberti L; Quaresima V; Biondi A; Bonfanti P; Castagnoli R; Casanova JL; Su HC; Notarangelo LD; Holland SM; Lionakis MS
Immunol Cell Biol; 2021 Oct; 99(9):917-921. PubMed ID: 34309902
[TBL] [Abstract][Full Text] [Related]
36. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes.
Kisand K; Link M; Wolff AS; Meager A; Tserel L; Org T; Murumägi A; Uibo R; Willcox N; Trebusak Podkrajsek K; Battelino T; Lobell A; Kämpe O; Lima K; Meloni A; Ergun-Longmire B; Maclaren NK; Perheentupa J; Krohn KJ; Scott HS; Husebye ES; Peterson P
Blood; 2008 Oct; 112(7):2657-66. PubMed ID: 18606876
[TBL] [Abstract][Full Text] [Related]
37. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].
Linkesch W; Gisslinger H; Ludwig H; Flener R; Sinzinger H
Acta Med Austriaca; 1985; 12(5):123-7. PubMed ID: 3914173
[TBL] [Abstract][Full Text] [Related]
38. [Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a].
Tichelli A; Gratwohl A; Delacrétaz F; Dazzi H; Stebler C; Wernli M; Holdener EE; Nissen C; Speck B
Schweiz Med Wochenschr; 1989 Sep; 119(39):1347-52. PubMed ID: 2799342
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms.
Saleiro D; Wen JQ; Kosciuczuk EM; Eckerdt F; Beauchamp EM; Oku CV; Blyth GT; Fischietti M; Ilut L; Colamonici M; Palivos W; Atsaves PA; Tan D; Kocherginsky M; Weinberg RS; Fish EN; Crispino JD; Hoffman R; Platanias LC
Nat Commun; 2022 Apr; 13(1):1750. PubMed ID: 35365653
[TBL] [Abstract][Full Text] [Related]
40. Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis.
Lazzarino M; Vitale A; Morra E; Gagliardi A; Bernasconi P; Torromeo C; Inverardi D; Burgio V; Castello A; Bernasconi C
Br J Haematol; 1989 Jun; 72(2):173-7. PubMed ID: 2757963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
